Thomas Aller, OD, provides in-depth overviews of each myopia management option—pharmacologic therapy, soft contact lenses, orthokeratology, spectacle lenses, and environmental and behavioral interventions—so clinicians can not only provide the right option to each patient, but also address the larger economic and societal burdens of myopia.
To outline the importance of myopia management as a progressive disease and to present effective treatment strategies, emphasizing the urgency of addressing myopia as a public health issue.
Key Findings:
Myopia is linked to increased risks of serious ocular conditions such as retinal detachment and glaucoma, with specific statistics to illustrate these risks.
Economic modeling shows significant productivity losses due to uncorrected myopia, quantified with relevant figures.
Interventions that slow myopia progression can reduce long-term healthcare costs, supported by case studies or examples.
Interpretation:
Myopia management should be integrated into standard eye care practices, emphasizing prevention and early intervention, with clear implications for practitioners.
Limitations:
The article does not address potential side effects of pharmacologic treatments, which could impact patient compliance.
Long-term efficacy of myopia management strategies remains to be fully established, highlighting the need for ongoing research.
Conclusion:
Effective myopia management can mitigate risks and economic burdens associated with the disease, highlighting the need for proactive strategies and a call to action for practitioners.
